Meanwhile, the documentation of known B-rapidly accelerated fibrosarcoma (BRAF) mutations, epidermal growth factor receptor (EGFR) exon 18–21 mutations, and anaplastic lymphoma kinase (ALK) translocations varied from 49.3% to 57%, as detailed in Table 2. This evidence concerns the gene BRAF and fibrosarcoma.